ROIV ▲ +1.6% - Roivant Sciences Ltd.
$ROIV ROIVW - Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Roivant Sciences shares rose 1.6% following the company's announcement that the FDA has approved LISRAYA™ (brepocitinib) for treating dermatomyositis in adults. The approval represents a significant milestone for the company, as LISRAYA is now available for commercial distribution in the U.S. market, potentially opening a new revenue stream for the biopharmaceutical company.
27-AUG-2026 03:29 PM ET
Share this post
More filings for $ROIV
ROIV ▲ +0.9% - Roivant Sciences Ltd.Nov 10, 2026ROIV ▲ +5.6% - Roivant Sciences Ltd.Nov 9, 2026ROIV ▲ +4.0% - Roivant Sciences Ltd.Nov 9, 2026ROIV - Roivant Sciences Ltd. - SEC Filing Update (05-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 5, 2026ROIV ▼ -0.2% - Roivant Sciences Ltd.Oct 29, 2026ROIV - Roivant Sciences Ltd. - SEC Filing Update (27-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 27, 2026
View full $ROIV filing history →💬 Comments
Loading comments…
Leave a comment
